Scynexis Shares Jump on $214 Million U.S. Government Contract for Antifungal Drug

Shares of Scynexis Inc. (NASDAQ:SCYX) jumped 10% in premarket trading on Monday after the biotechnology company announced it secured a major contract from a U.S. government agency. The agreement with the Biomedical Advanced Research and Development Authority (BARDA) is valued at up to $214 million to support the development of the company's antifungal drug candidate, SCY-247.

Contract Details

The contract is structured as a cost-share arrangement that could span a 10-year period if all options are exercised, Scynexis said in a statement. The funding is intended to advance SCY-247, a second-generation antifungal, from its current stage through a potential New Drug Application (NDA) submission for two separate indications.

An initial base period will provide approximately $18.5 million to move the oral and intravenous formulations of SCY-247 into a Phase 2 clinical trial for patients with invasive candidiasis. BARDA will cover eligible direct and administrative costs associated with the drug's development program.

Financial Implications

For Scynexis and its investors, the deal represents a significant source of non-dilutive funding, meaning the company can advance a key pipeline asset without issuing new shares that would dilute the ownership of existing stockholders. The company stated it expects to fund its share of the program's near-term costs within its existing operating plan.

Ad

Scynexis also affirmed that the new agreement does not alter its previously announced guidance for its lead product candidate, SCY-770, or its projected cash runway into 2029. This signals to the market that the new development effort will not disrupt its core strategic and financial plans.

About the Drug Candidate

SCY-247 is being developed to treat and prevent serious invasive fungal infections. The U.S. Food and Drug Administration (FDA) has already granted the candidate several important designations that can expedite development and review:

• Orphan Drug Designation
• Qualified Infectious Disease Product (QIDP) Designation
• Fast Track Designation

Scynexis reported positive Phase 1 data for the oral version of SCY-247 in September 2025. A Phase 1 study for the intravenous formulation has completed dosing, with data analysis currently underway.